Vaccination against the feline leukaemia virus: outcome and response categories and long-term follow-up

Hofmann-Lehmann, Regina; Cattori, V; Tandon, R; Boretti, Felicitas S; Meli, Marina L; Riond, Barbara; Pepin, A C; Willi, Barbara; Ossent, Pete; Lutz, H

doi:10.1016/j.vaccine.2006.12.022

Citations

Citation copied

Hofmann-Lehmann, R., Cattori, V., Tandon, R., Boretti, F. S., Meli, M. L., Riond, B., Pepin, A. C., Willi, B., Ossent, P., & Lutz, H. (2007). Vaccination against the feline leukaemia virus: outcome and response categories and long-term follow-up. Vaccine, 25(30), 5531–5539. https://doi.org/10.1016/j.vaccine.2006.12.022

Abstract

Feline leukaemia virus (FeLV) is a pathogen inducing fatal disease in cats worldwide. By applying sensitive molecular assays, efficacious commonly used FeLV vaccines that protect cats from antigenaemia were found not to prevent proviral integration and minimal viral replication after challenge. Nonetheless, vaccines protected cats from FeLV-associated disease and prolonged life expectancy. The spectrum of host response categories was refined by investigating plasma viral RNA loads. All cats initially fought similar virus loads, althou